



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Anagliptin

July 7, 2015

### Non-proprietary name

Anagliptin

### Safety measure

Precautions should be revised in the package insert.

In the Careful administration section, the following text should be added (underlined parts are revised):

Patients who have a history of abdominal surgery or intestinal obstruction

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following text should be added (underlined parts are revised):

Intestinal obstruction:

Intestinal obstruction may occur. Patients should be carefully monitored. If any abnormalities such as severe constipation, abdominal distension, sustained abdominal pain, or vomiting are observed, administration of this drug should be discontinued, and appropriate measures should be adopted.